GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Precipio Inc (NAS:PRPO) » Definitions » Beta

PRPO (Precipio) Beta : 0.98 (As of Dec. 12, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Precipio Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-12-12), Precipio's Beta is 0.98.


Precipio Beta Historical Data

The historical data trend for Precipio's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precipio Beta Chart

Precipio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.34 2.99 1.95 1.73 0.64

Precipio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.64 0.80 0.92 0.93

Competitive Comparison of Precipio's Beta

For the Diagnostics & Research subindustry, Precipio's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precipio's Beta Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Precipio's Beta distribution charts can be found below:

* The bar in red indicates where Precipio's Beta falls into.



Precipio Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Precipio  (NAS:PRPO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Precipio Beta Related Terms

Thank you for viewing the detailed overview of Precipio's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Precipio Business Description

Traded in Other Exchanges
N/A
Address
4 Science Park, New Haven, CT, USA, 06511
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Executives
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Ahmed Zaki Sabet officer: Chief Operations Officer 33 ANDYS DR, EAST HAVEN CT 06512
Ilan Danieli director, officer: Chief Executive Officer 14707 CALIFORNIA STREET, SUITE 5, OMAHA NE 68154
Matthew Gage officer: Chief Financial Officer 56 STAGECOACH CIRCLE, MILFORD CT 06460
David Seth Cohen director, 10 percent owner C/O STANDARD OIL, 299 BISHOP AVENUE, BRIDGEPORT CT 06610
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Randal J Kirk 10 percent owner 1881 GROVE AVENUE, RADFORD VA 24141
Kathleen Laporte director
Robert Patzig director THE GOVERNOR TYLER, 1881 GROVE AVENUE, RADFORD VA 24141
Michael A Luther director 21 CORPORATE CIRCLE, ALBANY NY 12203
Jeffrey Cossman director C/O PRECIPIO INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Carl Iberger officer: Chief Financial Officer C/O PRECIPIO, INC., 12325 EMMET STREET, OMAHA NE 68164
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Mark Rimer director, 10 percent owner C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511